The World Health Organization (WHO) released landmark Consolidated guidance and implementation handbook on hepatitis B and C, ...

Chronic hepatitis D coinfection affects an estimated 12 million people globally, with higher prevalence in low-income and middle-income countries, especially the African and Western Pacific regions.

When most people think about liver disease, they think about alcohol or hepatitis. What many don’t realize is that the most ...

The publication aims to help countries translate WHO’s global guidance into practical actions to accelerate progress toward ...

The World Health Organization (WHO) released landmark Consolidated guidance and implementation handbook on hepatitis B and C , to support countries ...

Hepatitis C virus (HCV) infects an estimated 50 million people worldwide, according to the World Health Organization, and remains a leading cause of cirrhosis and liver cancer. While antiviral drugs ...

Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an ...

Alcohol consumption leads to hormonal and inflammatory responses which affect both metabolic and cardiac systems ...

Chronic hepatitis B is a viral disease that affects the liver and greatly increases the risks of liver cirrhosis and ...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript March 5, 2026 Atea Pharmaceuticals, Inc. misses on ...